DrugPatentWatch Database Preview

Otsuka Pharm Co Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for OTSUKA PHARM CO LTD, and what generic alternatives to OTSUKA PHARM CO LTD drugs are available?

OTSUKA PHARM CO LTD has five approved drugs.

There are forty-four US patents protecting OTSUKA PHARM CO LTD drugs.

There are six hundred and fifty-one patent family members on OTSUKA PHARM CO LTD drugs in forty-three countries and twelve supplementary protection certificates in nine countries.

Summary for Otsuka Pharm Co Ltd

International Patents:	651
US Patents:	44
Tradenames:	5
Ingredients:	4
NDAs:	5

Drugs and US Patents for Otsuka Pharm Co Ltd

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka Pharm Co Ltd	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017		RX	Yes	Yes	9,941,931		Y
Otsuka Pharm Co Ltd	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017		RX	Yes	Yes
Otsuka Pharm Co Ltd	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		RX	Yes	No	9,125,939
Otsuka Pharm Co Ltd	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		RX	Yes	No	9,258,035		Y

Expired US Patents for Otsuka Pharm Co Ltd

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013	5,006,528*PED
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014	5,006,528*PED
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-002	Feb 28, 2013	5,006,528*PED
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-003	Sep 29, 2014	5,006,528*PED

Non-Orange Book US Patents for Otsuka Pharm Co Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,545,436	Body-associated receiver and method
9,649,066	Communication system with partial power source
8,722,680	Method of treating neurodegenerative diseases
8,604,041	Method of treating panic disorder

International Patents for Otsuka Pharm Co Ltd Drugs

Country	Document Number	Estimated Expiration
Ukraine	82561
Norway	20081631
Taiwan	201320961
Denmark	2268261

Supplementary Protection Certificates for Otsuka Pharm Co Ltd Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2014	Austria		PRODUCT NAME: ARIPIPRAZOL; REGISTRATION NO/DATE: EU/1/13/882 (MITTEILUNG) 20131119
427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
00408	Netherlands		PRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803
00669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Otsuka
• Otsuka America
• Otsuka America Pharm
• Otsuka Pharm